Neoadjuvant androgen deprivation therapy (ADT) before RP has been extensively tested and shows no significant improvement of long-term outcome for locally advanced prostate cancer.[3] Several studies have admitted that the decreasing in serum PSA and prostate volume was observed, and the optimal duration of neoadjuvant ADT may be at least 8 months for clinical benefit.[4,5] However, the extended waiting is likely to arise anxious in patients due for RP, or even worse result in disease progression for androgen-independent prostate cancer. The gene discussed is KLK3; the disease is Familial prostate cancer.